Harlan Waksal, Kadmon CEO (Richard Drew, AP Images)
May 21, 2020 10:24 AM EDTUpdated May 22, 03:39 AM
R&D

Kad­mon kicks off 're­al-time' NDA sub­mis­sion with an­oth­er look at 're­mark­able' chron­ic graft-ver­sus-host-dis­ease da­ta

Amber Tong

Six months af­ter re­port­ing “knock-your-socks-off kind of re­sults” for its chron­ic graft-ver­sus-host-dis­ease drug from an in­ter­im analy­sis, Kad­mon is back with a fi­nal slate …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times